-
TOPIC

Biomedicine: Companies

Related Topics:
Biomedicine: Companies
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
Global investors have reaped sizeable rewards from their investments in Hong Kong-listed biotech and pharmaceutical companies in the past year. Photo: Shutterstock
Banking & finance

Global funds, from BlackRock to Temasek, back China’s largest biotech firms

Global institutional investors have built up sizeable positions in firms including Innovent, 3SBio, WuXi Biologics, Jiangsu Hengrui, Akeso and BeOne.

US-China relations

Opinion | China has Trump 2.0 to thank for emerging stronger in tech and trade

videocam
Biomedicine: Industry Trends

Harbour BioMed stake in US drug developer shows Chinese firms’ growing clout

Made in China 2025

Exclusive | China challenges US in AI drug race, but rivals still reliant on each other

While US biotech firms increase use of Chinese clinical data, Chinese firms need US counterparts for monetisation, investor and scientist says.

Leung Chuen-yan, partner for healthcare investment at Value Partners Group. Photo: Edmond So
Made in China 2025

Novartis, SciNeuro deal offers hope for 55 million suffering from Alzheimer’s

SciNeuro’s anti-amyloid programme is one of the firm’s key strategic research and development priorities to target the brain disease.

videocam
Made in China 2025

China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens

Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 million in 2021.

Advertisement
Advertisement
Advertisement
Made in China 2025

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

Last year, China approved 76 innovative drugs, including 47 chemical drugs and 23 biologics. Photo: Shutterstock
Made in China 2025

Meow or never: China’s pudgy pets spark race for weight-loss drugs

Fosun and Huadong biotech labs eye feline obesity drugs as owners weigh cuteness against health risks.

Insilico

Insilico signs US$888 million AI drug deal days after Hong Kong IPO

Multi-year partnership with France’s Servier will use Insilico’s AI platform to explore novel cancer drugs.

Banking & finance

The ‘biology winter’ thaws: why investors are buying Hong Kong’s biotech IPOs

A wave of China out-licensing deals is feeding a biotech comeback in Hong Kong, where IPOs and follow-on placements are surging.

Healthcare firms now account for about a fifth of the more than 300 listing applications in the city. Photo: Shutterstock
Science

China’s biopharma sector ‘in prime position to challenge US leadership’

American commission issues stark warning, as analytics firm Clarivate reports that Chinese innovative drug development has entered new phase.

videocam
33
Illustration: Lau Ka-kuen
IPO

China vital to Insilico’s plan to build biotech’s AI ‘Einstein’ for new drugs

US firm, backed by Fosun and Tencent, expands research base in China as it develops an AI-powered drug-discovery tool.

Hong Kong healthcare and hospitals

Genomic sequencing puts Hong Kong at forefront of cancer care innovation

Scientist Aya El Helali says research speeds up cancer treatment discovery and helps the city bridge mainland China with global drug development.

Made in China 2025

China’s rising biotech clout on show in flurry of billion-dollar licensing deals

A burst of overseas licensing pacts is spotlighting China’s biotech sector, as Jacobio, Coherent Biopharma and Harbour BioMed land deals.

The latest transactions reflect a broader pattern of multinational drugmakers turning to Chinese biotechs for pipeline replenishment. Photo: Shutterstock
Banking & finance

Global firms turn to M&A in EVs and biotech to deepen China investment: KPMG

Survey of multinational corporations finds optimism in life sciences, healthcare and manufacturing, with half forecasting revenue growth.

Healthcare and life sciences are the top growth prospects over the next three to five years, according to multinational corporations. Photo: Xinhua
United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

China’s private sector

BeOne Medicines names R&D chief Wang Lai as president amid global expansion

BeOne generated global revenue of about US$3.8 billion last year, driven by its flagship products Brukinsa and Tevimbra.

Advertisement
Advertisement
Advertisement
Made in China 2025

China’s pharmaceutical industry transforms into a global innovation powerhouse

The China Pharmaceutical Innovation and Invention Index, a new gauge, highlights top drug makers on the mainland for the first time.

China is gaining a solid reputation as a pharmaceutical innovation hub, according to global consultancy Idea Pharma. Photo: AP
Made in China 2025

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves’ disease.

China manufacturing

China’s biotech firms may see ‘major breakthroughs’ within a decade. Here’s why

Strong manufacturing base a driving force behind overseas expansion, but industry leaders and analysts say hurdles remain.

videocam
Made in China 2025

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

Yao Pharma’s deal with the US pharmaceutical giant underscores China’s growing role in global biotech licensing.

The collaboration is “another significant milestone in Fosun Pharma’s strategy of innovation and internationalisation”, according to the company. Photo: Reuters
China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

A market once dominated by generics is now an AI-powered pharmaceutical hub drawing billion-dollar investments from the likes of Pfizer and GSK.

videocam
A worker checks the position of a feeding tray in a pharmaceutical manufacturing facility at the Hengrui Biomedical Industrial Park in Lianyungang in Jiangsu province, on December 13, 2021. Photo: Getty Images
Hong Kong stock market

China’s 3SBio seeks US$400 million in Hong Kong to boost drug pipeline

Share placement to help Shenyang-based firm advance clinical research in China and the US, expand reach of cancer and hair-loss drugs.

Biomedicine: Industry Trends

China’s clinical trial capacity matches US, attracts more global pharma firms

Growth of innovative clinical trials suggests that Chinese biotech firms’ pipeline of novel drug candidates is expanding, analysts say.

New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

Illustration: Henry Wong
Hong Kong healthcare and hospitals

Hong Kong biotech firm to back controversial sanitary pad HPV test with evidence

Dr Choi Pui-wah, founder of WomenX Biotech, also says she remains optimistic about Hong Kong as a tech destination despite government warning.

Dr Choi Pui-wah, founder of WomenX Biotech, also says she remains optimistic about Hong Kong as a tech destination. Photo: K. Y. Cheng
Biomedicine: Industry Trends

China biotech forum bills antibody cancer drugs as next-generation treatment

Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global strategies.

Greater Bay Area

BeOne Medicines to expand cancer-drug offerings in Hong Kong

Fresh off a profitable half year, a global drug company that started as an R&D firm in Beijing plans to expand production in Guangzhou.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement